

REVIEW ARTICLE

Open Access

Emerging molecular mechanisms in chemotherapy: Ca²⁺ signaling at the mitochondria-associated endoplasmic reticulum membranes

Martijn Kerkhofs¹, Mart Bittremieux¹, Giampaolo Morciano^{2,3}, Carlotta Giorgi², Paolo Pinton^{2,3,4}, Jan B. Parys¹ and Geert Bultynck¹

Abstract

Inter-organellar communication often takes the form of Ca²⁺ signals. These Ca²⁺ signals originate from the endoplasmic reticulum (ER) and regulate different cellular processes like metabolism, fertilization, migration, and cell fate. A prime target for Ca²⁺ signals are the mitochondria. ER–mitochondrial Ca²⁺ transfer is possible through the existence of mitochondria-associated ER membranes (MAMs), ER structures that are in the proximity of the mitochondria. This creates a micro-domain in which the Ca²⁺ concentrations are manifold higher than in the cytosol, allowing for rapid mitochondrial Ca²⁺ uptake. In the mitochondria, the Ca²⁺ signal is decoded differentially depending on its spatiotemporal characteristics. While Ca²⁺ oscillations stimulate metabolism and constitute pro-survival signaling, mitochondrial Ca²⁺ overload results in apoptosis. Many chemotherapeutics depend on efficient ER–mitochondrial Ca²⁺ signaling to exert their function. However, several oncogenes and tumor suppressors present in the MAMs can alter Ca²⁺ signaling in cancer cells, rendering chemotherapeutics ineffective. In this review, we will discuss recent studies that connect ER–mitochondrial Ca²⁺ transfer, tumor suppressors and oncogenes at the MAMs, and chemotherapy.

Facts

- Ca²⁺ fluxes between ER and mitochondria affect several cancer hallmarks, including apoptosis resistance, migration, and invasion.
- Oncogenes and tumor suppressors residing at the MAMs execute part of their cellular function by altering ER–mitochondrial Ca²⁺ transfer, thereby promoting or preventing cancer cell survival.
- Dependent on the cancer type and cancer stage, ER–mitochondrial Ca²⁺ transfer can either exert anti-tumorigenic effects like restoring apoptosis sensitivity or exert pro-tumorigenic effects like promoting metastatic behavior.
- Different chemotherapeutics rely on a Ca²⁺-signaling component to induce cancer cell death.
- Ca²⁺ signaling modulation can (re)sensitize or increase the responsiveness of cancer cells towards chemotherapeutics.

Correspondence: Geert Bultynck (geert.bultynck@kuleuven.be)

¹Department of Cellular and Molecular Medicine and Leuven Kanker Instituut, KU Leuven, Laboratory of Molecular and Cellular Signaling, Leuven, Belgium

²Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy

Full list of author information is available at the end of the article
Martijn Kerkhofs and Mart Bittremieux contributed equally to this work.
Edited by G. Melino

© The Author(s) 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Open questions

- How can Ca²⁺ signaling at ER–mitochondrial contact sites be modulated in a cancer-specific manner to fight cancer cell survival?

- Can ER–mitochondrial Ca^{2+} signaling events overcome dysregulated cell survival/apoptosis sensitivity in cells with altered oncogene and/or tumor suppressor function?
- What processes/regulation pathways underlie or control differences between ER–mitochondrial Ca^{2+} transfer in cancer cells vs. normal cells?
- How can Ca^{2+} -signaling modulation be applied to increase responsiveness and sensitivity to existing therapies and to induce cancer cell-specific cell death while sparing normal cells?
- Can Ca^{2+} signaling be applied in a cancer stage-specific manner, thereby promoting cell death and avoiding metastasis?
- What other molecular mechanisms, like the generation of ROS, exchange of lipids or alterations in protein composition, or ER–mitochondrial tethering at the MAMs impact or cooperate with Ca^{2+} signaling in anti-cancer chemotherapeutic actions?

Introduction: ER–mitochondrial Ca^{2+} signaling in cell death and survival


Mitochondria do not only fulfill the function of powerhouse of the cell but their function also encompasses more than merely providing the cell with ATP^{1,2}. Currently, mitochondrial function has been implicated in apoptosis, autophagy, cell proliferation, cellular senescence, and migration^{3–6}. Furthermore, mitochondrial function is impacted by the “state” of the mitochondrial network, which can range from highly connected to fragmented⁷. Nevertheless, mitochondria do not act as sole orchestrators of cellular processes. In fact, the mitochondrial network rather functions as a highly versatile signaling platform, closely connected to other cell organelles, like the endoplasmic reticulum (ER)⁸ and peroxisomes⁹. To allow for inter-organellar cross-talk, the different organelles are often located in close proximity to each other^{10,11}, like the ER and the mitochondria, which are connected through mitochondria-associated ER membranes (MAMs). These MAMs are defined as ER membranes that are in close apposition (10–50 nm) to the mitochondria and were first isolated as a distinct entity in the early 1990s^{11–13}. In recent years, MAMs were shown to contribute to various cellular functions like metabolism, autophagy, lipid synthesis but also cell survival and cell death^{8,14–18}. In this sense, the MAMs, like mitochondria, are highly dynamic signaling hubs where signals from different cellular pathways converge and are integrated^{15,19–21}.

One of the signals transferred between ER and mitochondria at the MAMs is the ubiquitous second messenger Ca^{2+} ^{22,23}. While $[\text{Ca}^{2+}]$ in the cytosol is maintained at low levels under resting conditions, the

bulk of intracellular Ca^{2+} is confined in the ER²². Ca^{2+} is predominantly released from the ER via the inositol 1,4,5-trisphosphate (IP_3) receptor (IP_3R), which is gated by IP_3 ²⁴, or the ryanodine receptor (RyR)²⁵. However, Ca^{2+} accumulation into the mitochondrial matrix requires Ca^{2+} transport across the outer mitochondrial membrane (OMM) and the inner mitochondrial membrane (IMM). At the OMM, Ca^{2+} transport is mediated via the high-conductance voltage-dependent anion channel 1 (VDAC1), while at the IMM, Ca^{2+} transport is mediated via the mitochondrial Ca^{2+} uniporter (MCU), the pore-forming unit in the MCU complex, consisting of MCU itself and its regulators^{26–28}. For a detailed description of MCU regulation we would like to refer to refs. ^{29,30}. The MAMs play an important role in mitochondrial Ca^{2+} uptake, since they provide a Ca^{2+} micro-domain, where Ca^{2+} levels are higher than in the bulk cytosol^{1,15}. This is necessary to sustain ER–mitochondrial Ca^{2+} signaling since the MCU has a low affinity for Ca^{2+} . Thus, the MAMs allow for efficient, ‘quasi-synaptic’ mitochondrial Ca^{2+} uptake upon ER Ca^{2+} release through the formation of a micro-domain^{1,15,31}. This emphasizes the importance of the MAMs as a signaling hotspot.

Mitochondrial Ca^{2+} signals are decoded differentially depending on their spatiotemporal characteristics (see Fig. 1). For example, cytosolic Ca^{2+} oscillations, efficiently transferred to the mitochondria through these contacts sites, drive mitochondrial metabolism. Moreover, several mechanisms account for the dynamic interplay between Ca^{2+} signals and mitochondrial metabolism. Ca^{2+} increases the activity of several rate-limiting enzymes of the tricarboxylic acid (TCA) cycle, including pyruvate, isocitrate, and α -ketoglutarate dehydrogenases³², while MCU transcription is controlled by the cAMP-responsive element binding protein, a Ca^{2+} -dependent transcription factor³³. Cells can also fine tune the level of Ca^{2+} oscillations that drive mitochondrial bioenergetics via a redox-nanodomain³⁴. Mitochondrial Ca^{2+} uptake triggers K^+ - and H_2O -influx into the mitochondrial matrix, leading to cristae compression and H_2O_2 release at the MAMs. This provides positive feedback on IP_3Rs , enhancing their ability to sustain Ca^{2+} oscillations³⁴. Other contributions of Ca^{2+} to cell metabolism are the stimulation of complex III of the electron transport chain, as well as stimulation of the ATP synthase and the adenine nucleotide translocase³⁵.

Ca^{2+} oscillations in the cytosol can also modify mitochondrial metabolism indirectly by activating ARALAR, a mitochondrial glutamate/aspartate transporter playing a central role in the malate/aspartate shuttle, which is strongly dependent on cytosolic Ca^{2+} signaling³⁶. Ca^{2+} binds to ARALAR and activates ARALAR-mediated glutamate and NAD(P)H transport into the mitochondria^{36–38}. Also, pyruvate production is Ca^{2+} dependent and is linked to the malate/aspartate shuttle, providing



pyruvate to the mitochondria^{39,40}. In addition, there is tissue-specific regulation, which determines the threshold for mitochondrial Ca^{2+} influx and its effects⁴¹. Liver cells and cardiomyocytes contain a high and a low ratio of mitochondrial Ca^{2+} uptake 1 (MICU1)/MCU, respectively, with MICU1 (together with MICU2) being an MCU regulator which affects the cooperativity of mitochondrial Ca^{2+} uptake^{42,43}. Therefore liver cells display a high cooperativity of mitochondrial Ca^{2+} uptake, while cardiac cells display a low cooperativity. This prevents the occurrence of mitochondrial Ca^{2+} signals in response to short-lasting Ca^{2+} transients and thus avoids mitochondrial Ca^{2+} overload even when the heart beats at high frequency⁴¹. Recently, it was shown that apart from affecting the cooperativity of mitochondrial Ca^{2+} uptake, MICU1, together with its paralog MICU2, inhibits the MCU at cytosolic Ca^{2+} concentrations lower than ~ 600 nm, thereby determining the relatively high threshold for MCU-mediated Ca^{2+} uptake⁴⁴. Compared to wild-type cells, loss of MICU1, which also results in loss of MICU2, lowers the threshold for MCU-mediated mitochondrial Ca^{2+} uptake to about 200 nM Ca^{2+} . Compared to

mitochondria lacking both MICU1 and MICU2, mitochondria containing MICU1 but not MICU2 display a higher threshold for mitochondrial Ca^{2+} uptake (~ 350 nM Ca^{2+}), indicating that MICU1 by itself can inhibit MCU. These observations indicate that MICU1 does not only control MCU cooperativity⁴³, but can also function as a gatekeeper of MCU⁴⁴. Moreover, MICU2 requires MICU1 to regulate MCU. MICU1's function as a gatekeeper is also important in vivo to prevent mitochondrial Ca^{2+} overload, as evidenced in MICU1-knockout animals, developing ataxia and muscle fatigue associated with elevated mitochondrial Ca^{2+} levels and reduced ATP levels⁴⁵. Finally, MICU1 and MICU2 were shown to bind the mitochondrial lipid cardiolipin, facilitating membrane anchoring of the complex and the fine-tuned Ca^{2+} -dependent regulation of the MCU by MICU1 and associated factors, like EMRE⁴⁴.

On the other hand, massive Ca^{2+} release from the ER causes mitochondrial Ca^{2+} overload, resulting in opening of the mitochondrial permeability transition pore (mPTP)^{46,47}, mitochondrial swelling, and subsequent cell death (Fig. 1)⁴⁸⁻⁵¹. Several mechanisms may account for

this. For instance, mitochondrial Ca^{2+} influx results in Ca^{2+} binding to cardiolipin, causing the disintegration of complex II and the release of the functionally active catalytic subunits in the mitochondrial matrix, providing a source of reactive oxygen species (ROS) that triggers the opening of the mPTP⁵². In addition to this, recent evidence emerged that mitochondrial Ca^{2+} could directly target the mPTP, resulting in a conformational change leading to its opening and to subsequent mitochondrial swelling⁵³.

Regulation of ER–mitochondrial Ca^{2+} signaling at the MAMs

Given its critical role in cell fate and survival, the composition and functional properties of the MAMs have to be carefully regulated and controlled. This occurs through a distinct set of proteins with a variety of cell biological properties and functions. Some of these proteins are directly involved in Ca^{2+} signaling at the MAMs, e.g. the IP_3R and VDACs^{49,54,55}, whereas others alter ER–mitochondrial Ca^{2+} signaling by acting through modulation of these Ca^{2+} -transport systems, e.g. promyelocytic leukemia protein (PML)⁵⁶ or phosphatase and tensin homolog (PTEN)⁵⁷. Other proteins modify the characteristics of the MAMs (e.g. their distance to the mitochondria), like the ER–mitochondria tethers mitofusin-2 (Mfn-2)^{58,59}, the protein kinase RNA-like endoplasmic reticulum kinase (PERK)⁶⁰, and the spacer protein fetal and adult testis expressed 1 (FATE1)⁶¹. We will focus on the proteins involved in ER–mitochondrial Ca^{2+} transfer at the MAMs, yet for a more extensive list of proteins present at the MAMs, we refer to ref. 13. For further insights on the role of Ca^{2+} -transport systems in cell death and survival, we refer to ref. 62. All the MAM components discussed in this section are schematically depicted in Fig. 2.

Since ER–mitochondrial Ca^{2+} transfer occurs at the MAMs, it is not surprising that several intracellular Ca^{2+} -transport systems reside at the MAMs. Both the IP_3R and VDAC1 can be found at the MAMs, where they are connected to each other via glucose-related protein of 75 kDa (GRP75)⁵⁵. Interestingly, isoform-specific functions for these channels at the MAMs have been discovered. Overexpression of VDAC1, VDAC2, as well as VDAC3 increased mitochondrial Ca^{2+} uptake, yet pro-apoptotic Ca^{2+} signals were only enhanced by VDAC1 overexpression⁶³. Moreover, VDAC1 is the only VDAC isoform that co-immunoprecipitated with the IP_3R ⁶³. Similarly, $\text{IP}_3\text{R}3$ seems to be the isoform that preferentially transmits pro-apoptotic Ca^{2+} signals to the mitochondria via the MAMs^{64,65}. Not only Ca^{2+} -release channels are located at the MAMs, the sarco-/endoplasmic reticulum Ca^{2+} ATPase (SERCA) pump localizes to the MAMs as well^{66–68}. SERCA pumps can influence




Fig. 2 Regulation of ER–mitochondrial Ca^{2+} signaling by oncogenes and tumor suppressors at the MAMs.

Arrow-headed full lines indicate a stimulatory effect, while bar-headed full lines indicate an inhibitory effect. Dot-headed lines indicate a tethering or a spacing effect, depending on the inward- or outward-facing dots, respectively. ER–mitochondrial Ca^{2+} transfer at the MAMs can be altered by different fine-tuning mechanisms. These mechanisms often involve oncogenes and tumor suppressors. An important tool to regulate the activity of the Ca^{2+} -signaling proteins at the MAMs is phosphorylation. Akt/PKB-mediated phosphorylation is known to suppress Ca^{2+} release via the IP_3R . However, this phosphorylation is counteracted by both PTEN, in a direct way, and PP2A, in an indirect way. This indirect mechanism consists of recruitment of PP2A to the IP_3R via PML. In turn, PP2A deactivates Akt/PKB by dephosphorylation and this relieves IP_3R inhibition. In addition, Ca^{2+} -signaling proteins like IP_3R , VDAC1, and SERCA interact with other proteins, which change their Ca^{2+} -signaling properties. Bcl-2-protein family members are among these proteins altering Ca^{2+} signals at the MAMs. Bcl-2 binds to the IP_3R , inhibiting pro-apoptotic Ca^{2+} signaling, while Bcl-XL interacts with VDAC1, inhibiting Ca^{2+} uptake through the OMM. p53, a master regulator of cell fate, on the other hand, interacts with SERCA, changing its oxidation state, thereby enhancing reuptake of Ca^{2+} in the ER. A third category of proteins that modifies Ca^{2+} signaling at the MAMs are those proteins that change the properties of the MAMs, e.g. ER-to-mitochondria distance at the MAMs. Mfn-2 in the ER is able to interact with Mfn-1 or Mfn-2 at the OMM, thereby tethering both organelles. On the other hand, there is FATE1 which has the opposite effect, namely spacing the mitochondria and the ER. The distance between ER and mitochondria at the MAMs is determined by these tethers and spacers and this, in turn, regulates the efficiency of ER–mitochondrial Ca^{2+} transfer

the properties of the MAMs since their activity determines how fast Ca^{2+} is cleared from the micro-domain⁶⁹. Moreover, SERCA pumps critically affect apoptotic sensitivity by controlling the steady-state filling level of the ER Ca^{2+} stores, which is determined by the balance between ER Ca^{2+} leak and ER Ca^{2+} uptake^{66,69–72}. Also for SERCA, isoform-specific functions exist: ER stress causes induction of SERCA1T, a truncated splice-variant of SERCA1. SERCA1T is a determinant of ER leakiness,

thereby promoting Ca^{2+} transfer to the mitochondria and thus supporting pro-apoptotic Ca^{2+} signaling^{73,74}.

As will be discussed further on, expression levels of the Ca^{2+} -signaling proteins critically determine the cell's Ca^{2+} -signaling properties. Furthermore, ER-mitochondrial Ca^{2+} signaling is fine-tuned by various oncogenes and tumor suppressors^{75,76}. These proteins may induce post-translational modifications that alter the Ca^{2+} -signaling properties of proteins at the MAMs⁷⁷. Particularly, phosphorylation of the IP_3R is a critical factor: Akt/protein kinase B (PKB) suppresses IP_3R -mediated Ca^{2+} release through phosphorylation⁷⁸, while tumor suppressors PTEN (direct dephosphorylation of IP_3R)⁵⁷ and PML (indirect dephosphorylation via sequestration of protein phosphatase 2A (PP2A) and subsequent Akt/PKB inhibition)⁵⁶ counteract this. Also, SERCA is a target for post-translational modification: p53 changes SERCA's oxidative state, promoting its ER Ca^{2+} -uptake activity and thus altering the net flux of Ca^{2+} released from the ER^{66,79,80}.

In addition, complex formation between Ca^{2+} -transport proteins like IP_3Rs and VDAC1 at the MAMs and tumor suppressors or oncogenes influences ER-mitochondrial Ca^{2+} transfer. Notably, several Bcl-2-protein family members, critical regulators of apoptosis, were shown to be present at the MAMs^{81,82} and can modify IP_3R -mediated Ca^{2+} -release^{77,83,84}. Bcl-2, an anti-apoptotic protein of the Bcl-2-protein family, inhibits the IP_3R directly by binding with its Bcl-2 homology (BH) 4 domain to the central, modulatory domain of the IP_3R ⁸⁵⁻⁸⁷. The BH4 domain also participates in overall stability of the Bcl-2 protein, affecting its IP_3R -inhibitory properties⁸⁸. Bcl-2's transmembrane domain is necessary for efficient in cellulo IP_3R inhibition⁸⁹. Indirectly, Bcl-2 changes IP_3R activity by providing a docking place at the IP_3R for protein phosphatase 1 (PP1), which inhibits IP_3R function by dephosphorylating the receptor⁹⁰. Bcl-2 also regulates IP_3R function by docking dopamine- and cAMP-regulated phosphoprotein of 32 kDa, a PP1 inhibitor, and the protein phosphatase calcineurin in a complex on the IP_3R ⁹¹. Thus, IP_3R activity is regulated by a negative feedback mechanism that prevents excessive, pro-apoptotic Ca^{2+} release from the ER. Besides Bcl-2, also Bcl-Xl and Mcl-1 can modulate IP_3R activity⁹²⁻⁹⁴. An extended discussion on the modulation of Ca^{2+} signaling by Bcl-2-protein family members can be found elsewhere^{82,95}.

Besides the IP_3Rs , Bcl-2-family members can also target mitochondrial Ca^{2+} -transport systems, including VDAC1. VDAC1/Bcl-2 complex formation inhibits VDAC1's function in mitochondrial Ca^{2+} transport^{96,97}. The BH4 domain of Bcl-2 appeared to play a critical role in VDAC1 regulation⁹⁸. Follow-up work revealed that the BH4 domain of Bcl-Xl is more effective in targeting and modulating VDAC1 than the BH4 domain of Bcl-2⁸¹.

Consequently, while both the BH4 domains of Bcl-2 and Bcl-Xl could prevent mitochondrial Ca^{2+} uptake, BH4-Bcl-2 acted at the level of IP_3Rs , while BH4-Bcl-Xl acted at the level of VDAC1⁸¹. To summarize, ER-mitochondrial Ca^{2+} transfer at the MAMs can be influenced through IP_3R -mediated Ca^{2+} release, VDAC1-mediated mitochondrial Ca^{2+} uptake, or modulation of the SERCA activity.

In addition to this, ER-mitochondrial Ca^{2+} transfer is altered by the number of MAMs and the distance between the ER and the OMM at the MAMs^{99,100}. Proteins that hold both membranes together are typically called tethers. An example of a tether at the MAMs is the GTPase Mfn-2 involved in mitochondrial fusion. Mfn-2 tethers ER and mitochondria through homo- and heterotypic interactions with Mfn-2 and Mfn-1, respectively^{59,101}. The importance of tethering was shown in Mfn-2-knockout cells, where ER-mitochondrial Ca^{2+} transfer was severely reduced¹⁰¹. Yet, the role of Mfn-2 as a tether has been debated, since another study showed that ablation of Mfn-2 does not impair the ER-mitochondrial connection but contrarily, tightens it^{58,101}. Here, Mfn-2 was proposed as a spacer that increases the distance at the MAMs and reduces ER-mitochondrial signaling. A typical spacer is FATE1, a cancer testis antigen, which is normally only expressed in the testis⁶¹. However, in certain cancers, FATE1 becomes upregulated and causes MAMs alterations⁶¹.

Rewiring Ca^{2+} signaling in cancer cells

The different possible layers of regulation of Ca^{2+} signaling impart an enormous flexibility to the cell concerning fine-tuning cellular processes in response to internal and external stimuli. However, this sensitive system can be hijacked to drive malignant transformations in the cell⁶. It is known that several types of cancer cells undergo an extensive rewiring of their Ca^{2+} -signaling machinery, favoring oncogenesis^{6,102,103}. At the level of the ER and the mitochondria, expression levels of Ca^{2+} -signaling proteins, including VDAC1, IP_3R , and SERCA, are often altered in cancer cells. For instance, VDAC1 expression levels are correlated with tumor growth and invasion in several types of cancer, e.g. non-small cell lung cancer and cervical cancer^{104,105}. In this regard, recently, genetic disruption of VDAC1 in cells from cancer xenograft models displayed decreased mitochondrial membrane potential and ATP content with a consequent low migration rate and tumor regression^{106,107}. Another example includes $\text{IP}_3\text{R1}$ down-regulation in bladder cancer cells, which attenuates cisplatin-mediated apoptosis through a decrease in ER-mitochondrial Ca^{2+} uptake, preventing mitochondrial Ca^{2+} overload^{108,109}. Remodeling of Ca^{2+} signaling in tumorigenesis is also documented by the significant reduction or loss of the SERCA3 isoform in transformed

colonic epithelial cells¹¹⁰. Different mechanisms may be responsible for the change in expression levels. Recently, two novel mechanisms dysregulated in several cancer types have been discovered to impact the proteasomal turnover and thus steady-state expression levels of IP₃R3 and the apoptotic sensitivity of cells¹¹¹. (i) The tumor suppressor PTEN competes with F-box/LRR-repeat protein 2 (FBXL-2), an E3 ubiquitin ligase component belonging to the Skip-Cullin1-F-box protein family¹¹², for binding to IP₃R3, thereby slowing down FBXL-2-mediated proteasomal degradation of IP₃R3¹¹³. This represents a novel mechanism by which loss of PTEN allows cancer cells to evade apoptosis, since pro-apoptotic mitochondrial Ca²⁺ transfer becomes impaired due to downregulation of the IP₃R3. (ii) The tumor suppressor BRCA1-associated protein 1 (BAP1), a deubiquitylating enzyme, promotes ER-mitochondrial Ca²⁺ transfer by stabilizing the IP₃R3¹¹⁴. BAP1 function is particularly impaired during prolonged environmental stress, associated with acquired inactivating mutations in BAP1 genes. Loss of BAP1 results in IP₃R3 downregulation, hampering the effective apoptotic clearance of damaged cells and favoring oncogenesis and malignant cell survival.

While MCU is not residing at the MAMs, its expression can be controlled in a tumor-specific manner, e.g. via microRNAs (miR)¹¹⁵. As such, miR-25, targeting MCU, was overexpressed in colon cancer cell lines and tumor samples, decreasing MCU expression compared to non-tumorigenic cells. Moreover, miR-25 overexpression in HeLa cells reduced mitochondrial Ca²⁺ accumulation, resulting in apoptosis resistance. In contrast, antagonizing miR-25 expression using antagomirs re-sensitized colon cancer cells to Ca²⁺-dependent apoptotic stimuli, like H₂O₂ and ceramide. Interestingly, MCU may prevent tumor cell survival in an early stage, but can become a pro-malignant factor in late-stage tumors, like triple negative breast cancer cells¹¹⁶. These cells express high levels of MCU, correlating with tumor size and lymph node infiltration, which negatively impact survival outcome. The mechanisms involved MCU-dependent uptake of Ca²⁺ into the mitochondrial matrix and subsequent generation of ROS that stabilized hypoxia-inducible factor-1 α , a transcription factor driving the expression of genes involved in cancer migration and invasion^{116,117}.

Furthermore, oncogenes like Akt/PKB and FATE1, and tumor suppressors like PML and PTEN, can play additional roles in the development of cancer via Ca²⁺-signaling modulation¹⁰⁸. A striking example of this is apoptotic resistance. Since mitochondrial Ca²⁺ overload is involved in apoptotic cell death, modifying ER-mitochondrial Ca²⁺ transfer at the MAMs alters apoptotic sensitivity⁴⁸. Cancer cells can gain resistance against cell death, e.g. by overexpressing proteins that suppress IP₃R-mediated Ca²⁺ signaling, like Akt⁷⁸, or by increasing the intermembrane

distance at the MAMs (e.g. FATE1), thereby rendering ER-mitochondrial Ca²⁺ transfer less efficient⁶¹. These mechanisms are not only supporting basic cancer cell characteristics, but also underlie resistance against chemotherapy. Cell death induction strategies still play a central role in the fight against cancer. While selective oncogene inhibitors, like venetoclax/ABT-199 for Bcl-2 inhibition, emerged and entered the clinic¹¹⁸, chemotherapy remains a very effective way to eradicate tumor cells by triggering cell death¹¹⁹.

Besides ER-mitochondrial Ca²⁺ signaling, Ca²⁺ fluxes across the plasma membrane can affect cancer properties as well. We would like to refer to other excellent reviews regarding this topic¹²⁰⁻¹²², as in this section, we would like to focus on chemotherapeutic drugs that act on Ca²⁺ signaling at the MAMs.

Chemotherapy and Ca²⁺ signaling in cancer cells

Ca²⁺ signaling appears to be a major contributor to the cytotoxic effects of chemotherapy. Many chemotherapeutic agents trigger a rapid onset of cytosolic [Ca²⁺] rises¹²³. Furthermore, shifts in cytosolic [Ca²⁺] have been proposed as early markers for cytotoxicity in cells in response not only to H₂O₂ or staurosporine but also to chemotherapeutics like gossypol or arsenic trioxide (ATO)¹²³. The mechanism of these early cytosolic [Ca²⁺] elevations is not always fully understood, but may in part depend on the presence of p53. Upon chemotherapeutic treatment, extra-nuclear p53 can accumulate at the ER membranes where it binds SERCA and activates its ER Ca²⁺-uptake activity^{66,79, 80,124,125}. Thus, SERCA activation will augment the ER Ca²⁺-store content, overfilling the ER with Ca²⁺ and thus increasing the likelihood for spontaneous ER Ca²⁺-release events¹²⁶. However, the occurrence of shifts in cytosolic [Ca²⁺] may not be a general phenomenon, as on-target Bcl-2 inhibitors, like ABT-737¹²⁷ and venetoclax/ABT-199¹²⁸, do not trigger these early cytosolic [Ca²⁺] elevations, even not in cancer cells that are dependent on Bcl-2 for their survival. The reason for these varying responses are not fully understood, but may actually relate to the mechanism of action of the drug applied and in particular whether p53 is involved.

Here, we will discuss the chemotherapeutic agents that act via ER-mitochondrial Ca²⁺ signaling. These chemotherapeutics are summarized in Table 1, whereas a schematic representation of their function at the MAMs is provided in Fig. 3.

Arsenic trioxide

Acute promyelocytic leukemia (APL) is almost always characterized by a t(15;17) chromosomal translocation, resulting in a PML/retinoic acid receptor (RAR) α fusion protein that hinders the differentiation of hematopoietic cells by inhibiting gene transcription^{129,130}. APL patients

Table 1 Overview of the different chemotherapeutic agents that act through mechanisms related to the MAMs and/or targets localized at the MAMs

Chemotherapy	Target protein	Mechanism of action at MAMs	Functional effect	Cancer type	Reference
Arsenic trioxide	PML	Elevating PML levels, which results in an increased IP ₃ R-mediated ER-mitochondrial Ca ²⁺ transfer	Repression of autophagy	Acute promyelocytic leukemia	17
Cisplatin	Unknown	Increasing ER-mitochondria contact sites and subsequent mitochondrial Ca ²⁺ overload	Apoptosis	Ovarian cancer, non-small cell lung cancer & bladder cancer	140
ABT-737	Bcl-2 & Bcl-XI	Alleviating the decrease in IP ₃ R-mediated Ca ²⁺ release by Bcl-2 Antagonizing the inhibitory action of Bcl-2 on MAM formation induced by cisplatin	(Re)sensitization to cisplatin therapy	Ovarian cancer & cholangiocarcinoma	143,158
Resveratrol	ATP synthase	Augmenting mitochondrial Ca ²⁺ due to impaired SERCA activity in the MAMs as a consequence of ATP synthase inhibition	Apoptosis	Broad spectrum	166
Adriamycin	p53	Increasing SERCA activity and ER Ca ²⁺ loading via p53, which is enriched at ER & MAMs	Apoptosis	Broad spectrum	66
Mitotane	SOAT1	Provoking the accumulation of toxic cholesterol lipids	Apoptosis	Adrenocortical carcinoma	61

are mostly treated by a combination of all-*trans* retinoic acid and ATO therapy, which stimulates APL cell differentiation by triggering proteasomal degradation of the PML/RAR α fusion protein^{129,131–133}. This treatment approach results in high APL cure rates, reflected by high complete remission and overall survival percentages^{129,132}.

ATO also influences ER-mitochondrial Ca²⁺ signaling, thereby repressing autophagy in cancer cells¹⁷. Autophagy is an important pro-survival pathway in malignant cells that experience oncogenic stress, as missing nutrients can be delivered to the cells via this process^{17,134}. The tumor suppressor PML, which is localized at the MAMs, represses autophagy by promoting ER-mitochondrial Ca²⁺ transfer and mitochondrial respiration¹⁷. Hence, PML is often downregulated in cancer cells¹³⁵. Loss of PML results in reduced IP₃R-mediated Ca²⁺ transfer from the ER to the mitochondria, leading to decreased mitochondrial Ca²⁺ levels, thereby diminishing mitochondrial respiration and ATP production¹⁷. This triggers activation of AMP-activated protein kinase, which stimulates pro-survival autophagy by a mechanism involving mechanistic target of rapamycin and unc-51-like kinase 1 pathways^{136,137}. Interestingly, this autophagic process is repressed in APL cells treated with ATO¹⁷. Short-term treatment of these cells with ATO promotes the selective degradation of the PML/RAR α fusion protein, but not of PML. Furthermore, exposure to ATO increases the PML levels at ER-mitochondria contact sites in a p53-

dependent manner (Fig. 3). Besides a block in autophagy, ATO-treated cells also displayed reduced resistance to metabolic stress¹⁷. Furthermore, this study implicates that the response of tumor cells characterized by loss of PML to chemotherapeutic agents can be improved by inhibiting autophagy.

Cisplatin

Cisplatin is a chemotherapeutic agent used to treat numerous human cancers, including lung, ovarian, head and neck, bladder, and testicular cancer¹³⁸. The anticancer activity of this platinum-based drug has been linked to its ability to covalently bind purine residues on DNA^{138,139}. This interaction causes DNA damage, interferes with DNA repair mechanisms, and blocks cell division, ultimately leading to apoptotic cell death. Unfortunately, cisplatin treatment has been associated with considerable side effects, like cardiotoxicity, hepatotoxicity, nephrotoxicity, and toxicity of other organs, and drug resistance is often acquired during therapy as well¹³⁸. To overcome these obstacles, combination therapies of cisplatin with other anti-cancer drugs, including paclitaxel, doxorubicin, and gemcitabine, form the basis for treatment of many human cancers¹³⁸.

Interestingly, the ER-mitochondrial Ca²⁺ signaling pathway contributes to cisplatin-induced cell death. Treatment of SKOV3 human ovarian cancer cells with cisplatin increased the number of ER-mitochondria contact sites, causing a Ca²⁺ flow from the ER to the




Fig. 3 The action of chemotherapeutic agents at the MAMs.

Arrow-headed full lines indicate a stimulatory effect, while bar-headed full lines indicate an inhibitory effect. Dashed lines indicate an indirect effect. Dot-headed lines indicate a tethering or a spacing effect, depending on the inward- or outward-facing dots, respectively. This figure constitutes an overview of the chemotherapeutics discussed in this review and how they act on the MAMs. Resveratrol is an inhibitor of the ATP synthase. This inhibitory effect leads to less ATP being available for SERCA pumps to ensure rapid reuptake of Ca^{2+} in the ER, creating a high local Ca^{2+} concentration. This, together with an increased ER-mitochondrial tethering, underlies the cancer cell-specific killing by resveratrol. ATO, another chemotherapeutic agent, increases PML levels at the MAMs. This restores ER-mitochondrial Ca^{2+} transfer in cancer cells that have a decreased or impaired PML activity and consequently suppresses pro-survival autophagic flux. A third chemotherapeutic drug, cisplatin, covalently binds to DNA, inducing DNA damage and causing apoptotic cell death, involving ER-mitochondrial Ca^{2+} signaling. However, cancer cells overexpressing Bcl-2 are more resistant to cisplatin-induced cell death, seemingly via a dual mechanism: the inhibition of Ca^{2+} release from the ER and the inhibition of an increase in ER-mitochondrial contact points resulting from cisplatin treatment. In this sense, administering ABT-737, a Bcl-2-inhibiting BH3 mimetic, to cancer cells, restored sensitivity to cisplatin. Furthermore, there is adriamycin, which renders ER-mitochondrial Ca^{2+} transfer more efficient by enriching p53 at the SERCA pumps. This leads to an increased activity of SERCA, increasing the ER Ca^{2+} levels and sensitizing cells towards apoptosis. Lastly, mitotane is an inhibitor of SOAT1, resulting in increased free cholesterol and lipid-induced ER stress. However, sensitivity towards mitotane is dependent on the expression levels of FATE1, a spacer protein at the MAMs. Increased levels of FATE1 are responsible for decreased mitochondrial Ca^{2+} uptake and in this way render cancer cells less sensitive towards apoptosis

mitochondria (Fig. 3)¹⁴⁰. This resulted in high mitochondrial Ca^{2+} levels, which triggered apoptosis in the cisplatin-treated ovarian cancer cells. Furthermore, the expression level of the anti-apoptotic protein Bcl-2, which is overexpressed in many tumors and drives tumorigenesis and chemoresistance, seems to be a determinant for

the sensitivity of cancer cells to cisplatin (Fig. 3). In non-small cell lung cancer and bladder cancer, cisplatin sensitivity could be enhanced by downregulating Bcl-2^{141,142}. In addition, downregulation of Bcl-2 in SKOV3 cells with siRNA increased the cytoplasmic and mitochondrial Ca^{2+} levels as well as the number of ER-mitochondria contact points after cisplatin treatment, thereby increasing the sensitivity to the chemotherapeutic agent¹⁴³. Hence, Bcl-2 seems to form a potential therapeutic target to improve cisplatin therapy of ovarian cancer cells. Additionally, in neuroblastoma cells, cisplatin-induced cell death was preceded by a rise in cytosolic $[\text{Ca}^{2+}]$ ¹⁴⁴. Cisplatin treatment also increased the expression levels of several Ca^{2+} -transport systems, including IP₃R3, RyR3, and the S100 Ca^{2+} -binding protein A6. Therefore, cisplatin-induced cell death can be enhanced by pharmacological modulators of Ca^{2+} -regulatory proteins, like the SERCA inhibitor thapsigargin¹⁴⁴.

BH3 mimetics

BH3 mimetics are a class of anti-cancer drugs inhibiting the function of anti-apoptotic Bcl-2-protein family members like Bcl-2, Bcl-XL, and Mcl-1^{145-147,148}. This causes pro-apoptotic Bcl-2-family members, which are sequestered by their anti-apoptotic counterparts through a hydrophobic cleft, consisting of the BH1, BH2, and BH3 domain, to be released, resulting in apoptosis^{145,146}. This is an effective anti-cancer therapy in cancers that rely on an upregulation of the anti-apoptotic Bcl-2-family proteins for their survival. Several molecules have been developed as BH3 mimetic drug, notably ABT-737, which targets the hydrophobic cleft of both Bcl-2 and Bcl-XL, its orally available analog ABT-236 (navitoclax) and ABT-199 (venetoclax), which solely targets the hydrophobic cleft of Bcl-2¹⁴⁵. While these drugs are specifically developed to suppress the canonical, anti-apoptotic function of the Bcl-2-protein family members at the mitochondria, it seems that their intracellular effects are more complex.

Thrombocytopenia is an important side effect caused by ABT-737 and ABT-263, since these BH3 mimetic drugs inhibit the function of Bcl-XL, which is essential for platelet formation and survival¹⁴⁹⁻¹⁵¹. Dysregulation of intracellular Ca^{2+} homeostasis might underlie ABT-737- and ABT-263-induced thrombocytopenia, as addition of ABT-263 to platelets triggered an acute rise in cytosolic Ca^{2+} levels¹⁴⁹. However, a direct link between deranged Ca^{2+} signaling and platelet dysfunction was not provided since this effect was only observed upon addition of relatively high ABT-263 concentrations (10 μM), whereas platelet function was already decreased at much lower concentrations (100 nM–1 μM)¹⁴⁹. Furthermore, prolonged treatment of platelets with ABT-263 and ABT-737 depleted the intracellular Ca^{2+} -storage organelles^{149,152}.

However, it was not clear whether the effects on Ca^{2+} signaling were the cause of platelet apoptosis or whether they were the consequence of platelets being in late-stage apoptosis due to Bcl-Xl inhibition. Our lab excluded a direct impact of ABT-737 on intracellular Ca^{2+} signaling, since ABT-737 application did not affect thrombin-induced Ca^{2+} signaling in platelets nor ATP-induced Ca^{2+} signaling in HeLa cells¹²⁷. Moreover, SERCA activity and IP_3R -mediated Ca^{2+} release were unaffected by ABT-737. These results argue against a proximal role of Ca^{2+} -signaling dysregulation in platelet dysfunction and apoptosis induced by ABT-737.

On the other hand, for ABT-199/venetoclax, which only targets the hydrophobic cleft of Bcl-2, no evidence was found for a perturbation of Ca^{2+} homeostasis^{128,148,153}. In several human and mouse cell models, ABT-199 did not trigger cytosolic Ca^{2+} release events by itself nor did it affect agonist-induced IP_3R -mediated Ca^{2+} signaling¹²⁸. Also, clearance of Ca^{2+} from the cytosol after agonist application was not affected. Furthermore, ABT-199 did not interfere with the inhibition of IP_3R caused by overexpression of Bcl-2¹²⁸. Nevertheless, it seems that there is an interplay between ABT-199-induced cell death in Bcl-2-dependent cancer cells and basal Ca^{2+} signaling, since chelating intracellular Ca^{2+} using BAPTA-AM enhanced ABT-199-induced cell death¹²⁸. The mechanisms underlying this phenomenon remain unclear, but might be due to downregulation of anti-apoptotic Bcl-2-family members or upregulation of pro-apoptotic Bcl-2-family members. Furthermore, Bcl-2-dependent cancer cells can be sensitized towards ABT-199 by the application of BIRD-2¹⁵⁴, a BH4-domain inhibitor of Bcl-2 that triggers toxic Ca^{2+} -release events and apoptosis in various cancer cells, including chronic lymphatic leukemia, diffuse large B-cell lymphoma, multiple myeloma, follicular lymphoma, and lung cancer cells^{86,154–156}. Further, it appears that BIRD-2 upregulates Bim in a Ca^{2+} -dependent manner, thereby likely accounting for an increased sensitivity of the cells towards BH3 mimetics like ABT-199 application^{154,157}. As such, BIRD-2 and ABT-199 can act synergistically to trigger cell death in Bcl-2-dependent cancers. Finally, it appears that cancer cells that are less sensitive to BH3 mimetics are more sensitive to BIRD-2 and vice versa^{154,156,157}.

Interestingly, ABT-737 can enhance the chemotherapeutic effectivity of cisplatin in cholangiocarcinoma (CC) as well as in ovarian cancer cells^{143,158}. In the latter, ABT-737 treatment increased the cisplatin-induced growth inhibition and apoptosis in cisplatin-resistant cells, hence restoring their sensitivity to the chemotherapeutic agent¹⁴³. Combination therapy with cisplatin and ABT-737 of the cisplatin-resistant ovarian cancer cells increased the number of ER-mitochondria contact sites induced by cisplatin, stimulating Ca^{2+} transfer from the

ER to the cytosol and the mitochondria (Fig. 3). Hence, ABT-737 can reverse cisplatin resistance of ovarian cancer cells by enhancing ER-associated and mitochondria-mediated apoptosis¹⁴³. Furthermore, ABT-737 sensitized CC cells to cisplatin therapy by regulating mitochondrial dynamics¹⁵⁸. ABT-737 stimulated CC cells to undergo apoptosis after cisplatin treatment by promoting mitochondrial fission and inducing mitophagy. Therefore, ABT-737 combined with cisplatin might be an effective strategy to treat CC patients¹⁵⁸. This also provokes the question in what manner Bcl-2-protein family members regulate the dynamics of the MAMs in cancer.

Of note, earlier versions of Bcl-2-inhibiting molecules can dysregulate intracellular Ca^{2+} homeostasis. HA14-1 and stabilized HA14-1s can deplete ER Ca^{2+} stores by inhibiting the SERCA Ca^{2+} pump^{127,159}. In a separate study, both HA14-1 and BH3I-2' trigger Ca^{2+} release from the ER of pancreatic acinar cells through IP_3R - and RyR-mediated mechanisms, elevating cytosolic Ca^{2+} levels, a feature that contributes to their cell death properties¹⁶⁰. Here, it was proposed that dissociation of Bax from Bcl-2 using these drugs sensitize IP_3Rs and RyRs to cytosolic Ca^{2+} . Excitingly, the ability of HA14-1 and BH3I-2' to increase cytosolic Ca^{2+} levels in pancreatic acinar cells was strictly dependent on the presence of Bax, while the presence of Bcl-2 and Bak was not critical for this process. It was proposed that Bax, released from Bcl-2, can induce Ca^{2+} leak from the ER, either by itself or by acting on ER Ca^{2+} -leak channels like IP_3Rs ¹⁶¹. Yet, further work using selective Bcl-2 inhibitors is needed to validate this model. A detailed discussion on the role of BH3 mimetics and Ca^{2+} signaling is provided elsewhere^{148,162}.

Resveratrol

Resveratrol is a natural polyphenol produced in response to stressful conditions by various plant species. It is found in several foodstuffs, including grapes, mulberries, and peanuts, and has been attributed beneficial health effects since the early 1990s^{163–165}. It is known as a multi-target agent exhibiting antioxidant, anti-inflammatory, and immunomodulatory activities. This pleiotropic compound affects cell proliferation, differentiation, apoptosis, and autophagy and attenuates many age-related chronic complications, such as metabolic, cardiovascular, and neurodegenerative diseases^{164,165}. Furthermore, resveratrol has been used as a chemopreventive and chemotherapeutic agent in many types of cancer^{163–165}. For instance, it has been used in clinical trials conducted in patients with colon, colorectal, and gastrointestinal cancers as well as in a trial examining the effects of resveratrol in the prevention of cancer in healthy participants¹⁶³. Remarkably, resveratrol functions as a

specific anticancer agent with limited toxicity in normal cells¹⁶³. However, the exact mechanism by which resveratrol specifically kills cancer cells remains unclear.

Recently, it was suggested that the difference in ATP demand between cancer and somatic cells underlies the cancer cell-specific toxicity of resveratrol¹⁶⁶. Cancer cells are characterized by a very high ATP demand at the ER because of immense protein folding activities going on at this organelle^{167,168}. Therefore, tethering of the ER and the mitochondria, which produce ATP via the ATP synthase localized in the IMM, is strongly enriched in cancer cells, warranting high ATP levels in the proximity of the ER^{169,170}. However, resveratrol, which acts as an inhibitor of the F1 subunit of the ATP synthase^{171–174} exploits the enhanced ER–mitochondria coupling in malign cells to kill these cells exclusively (Fig. 3). As a result of ATP synthase inhibition in resveratrol-treated cells, ATP formation is reduced, by which the high energy demand of cancer cells is not met anymore¹⁶⁶. As a consequence of the reduced ATP content at the mitochondria, SERCA activity within the MAMs is decreased, hampering Ca²⁺ reuptake into the ER, provoking not only an accumulation of Ca²⁺ in the micro-domain between ER and mitochondria¹⁶⁶, but also leading to a depletion of the ER via the Ca²⁺-leak channels¹⁷⁵. Both phenomena result in a high local Ca²⁺ concentration and because of the enforced ER–mitochondria coupling in cancer cells, mitochondrial Ca²⁺ accumulation is consequently enhanced upon treatment with resveratrol. Due to the fact that cancer cells are more sensitive to ATP synthase inhibition than healthy cells, resveratrol will especially trigger apoptotic cell death via mitochondrial Ca²⁺ overload in those cells¹⁶⁶.

Adriamycin

Adriamycin, also known as doxorubicin, is an anthracycline-type drug that has been used in cancer therapy for many years^{176,177}. It is characterized by a broad-spectrum antineoplastic activity, although its mechanism of action is complex. Adriamycin inhibits topoisomerase II, intercalates in DNA, and generates free radicals, hence inhibiting biosynthesis of macromolecules and leading to oxidative stress^{177–179}. Ultimately, adriamycin treatment results in apoptotic cell death. This chemotherapeutic agent is commonly used to treat various types of cancer, including breast, ovarian, bladder, stomach, and lung cancer¹⁷⁷. However, the applicability of adriamycin as anticancer therapy is restricted due to its severe toxic effects in healthy tissues^{176,177,179}. Especially cardiotoxicity forms a major concern during adriamycin therapy, limiting the dose that can be administered to patients^{177,180}. To circumvent the adverse effects of adriamycin, several drug delivery systems have been used^{176,177,179}. For instance, adriamycin-induced toxicity

is decreased when using liposomal, nanoparticle, or hydrogel drug formulations.

Adriamycin also renders cells more prone to programmed cell death by influencing the ER–mitochondrial Ca²⁺ signaling axis^{66,79,181}. The tumor suppressor p53, an important transcription factor regulating DNA repair, cell-cycle arrest, and apoptosis, modulates Ca²⁺ homeostasis by stimulating the SERCA pump located at the ER and the MAMs⁶⁶. As a consequence, Ca²⁺ accumulation in the ER is enhanced. Interestingly, treatment of cancer cells with adriamycin caused an enrichment of p53 at the ER and the MAMs (Fig. 3)^{66,79}. This induction of p53 by adriamycin led to higher ER Ca²⁺ levels and higher cytosolic and mitochondrial [Ca²⁺] increases evoked by agonist stimulation⁶⁶. Moreover, Ca²⁺ transport from the ER to the mitochondria was increased by adriamycin, allowing apoptotic stimuli to rapidly overload the mitochondria with Ca²⁺, resulting in apoptotic cell death. Hence, chemotherapeutic agents like adriamycin boost toxic ER–mitochondrial Ca²⁺ signaling through modulation of the Ca²⁺ homeostasis at the MAMs, thereby triggering apoptotic cell death in cancer cells^{66,79}.

Another way in which Ca²⁺ signaling is able to contribute to the sensitivity of cancer cells to chemotherapeutics, is the induction of autophagy¹⁸². Recently, valproic acid was found to reduce the intracellular availability of IP₃, hence blocking Ca²⁺ transfer to the mitochondria and altering the AMP-activated protein kinase 1/2–mechanistic target of rapamycin pathway. This lack of ER–mitochondrial signaling induced autophagy, thereby sensitizing cancer cells to adriamycin¹⁸².

Lipid-interfering strategies

A recent insight in tumor biology is the occurrence of dysregulation of lipid metabolism in cancer cells and its importance to several aspects of cancer cell function and survival. Consequently, disrupting or altering lipid homeostasis in cancer cells might be an efficient way of inducing cell death¹⁸³. One of the ways to induce apoptosis in this manner in cancer cells is the use of chemotherapeutics that increase intracellular, free cholesterol¹⁸³. Alkyl phospholipids were observed to hinder cholesterol transport from the mitochondria to the ER, avoiding its esterification, whereas cholesterol synthesis and incorporation was increased at the same time in glioblastoma cells¹⁸⁴. In macrophages it was found that this free cholesterol accumulates at the ER, inhibiting SERCA pumps and causing depletion of the ER. This results in an increased transfer of Ca²⁺ to the mitochondria and subsequent apoptosis¹⁸⁵.

Another chemotherapeutic drug that acts on lipid metabolism is mitotane, a derivative of the insecticide dichlorodiphenyl-trichloroethane. Mitotane is the only

chemotherapeutic drug approved for the treatment of adrenocortical carcinoma (ACC), one of the deadliest endocrine malignancies^{186–189}. In ACC cells, but not in non-adrenal cancer tissues, mitotane counteracts tumor growth and steroid hormone production^{186,190}. These effects of mitotane are believed to be the result of the inhibition of the sterol-*O*-acyl-transferase 1 (SOAT1), an enzyme that protects cells against the harmful effects of free cholesterol by transforming it into cholesterol esters. Because of SOAT1 inhibition, mitotane therapy leads to the accumulation of toxic lipids, including free cholesterol and oxysterols, inside ACC cells, which triggers lipid-induced ER stress¹⁹⁰. Moreover, in ACC tissue samples, SOAT1 expression correlated with the response to mitotane treatment.

Interestingly, mitotane-induced apoptosis in ACC cells also depends on FATE1 expression⁶¹. Under physiological conditions, FATE1 expression is restricted to the testis and adrenal gland, while FATE1 overexpression is observed in a variety of cancers^{191,192}. In ACC cells, FATE1 expression is controlled by the steroidogenic factor-1 (SF-1), a transcription factor that is important for adrenal development and plays a role in the formation of adrenocortical tumors^{61,191}. FATE1, localized at the MAMs where it uncouples the ER and mitochondria, decreases mitochondrial Ca²⁺ uptake in ACC cells⁶¹. In this way, FATE1 protects cancer cells from Ca²⁺-dependent apoptotic stimuli. Furthermore, FATE1 expression conferred mitotane resistance to ACC cells, when this chemotherapeutic drug was used in a dose that falls inside the therapeutic window for ACC patients, whereas knockdown of FATE1 in these cells increased the sensitivity to the drug⁶¹. FATE1 probably protects against mitotane-induced apoptosis because of its localization in the MAMs⁶¹. Mitotane inhibits the SOAT1 enzyme¹⁹⁰, which is also localized in the MAMs, resulting in the accumulation of toxic cholesterol lipids. Hence, in the presence of FATE1 mitotane-mediated SOAT1 inhibition may be less efficient (Fig. 3)⁶¹. Interestingly, FATE1 expression in ACC tumor cells can even be used as a prognosis indicator since FATE1 expression is inversely correlated with the overall survival of ACC patients⁶¹.

Conclusion

In conclusion, MAMs form important intracellular signaling platforms, allowing for Ca²⁺-encoded messages between the ER and the mitochondria. This ER–mitochondrial Ca²⁺ exchange can be altered during cancer development to promote cancer hallmarks like evasion of apoptosis, excessive cell proliferation, and a metabolic rewiring. In addition, many chemotherapeutics act via Ca²⁺ signaling at the MAMs (Fig. 3). Moreover, chemotherapeutics can interfere with the function of oncogenes and tumor suppressors, thereby altering

ER–mitochondrial Ca²⁺ transfer. In this sense, chemotherapeutics that modify ER–mitochondrial Ca²⁺ signaling can be used to increase the response of cancer cells towards therapeutics that harbor a Ca²⁺ component in their working mechanism.

Acknowledgements

G.B. and J.B.P. are supported by grants from the Research Foundation—Flanders (FWO) (grants G.0571.12N, G.0819.13N, G.0634.13N, G.0C91.14N, G.0927.15N, and G.0A34.16N) and the Research Council—KU Leuven (OT14/101). M.B. and M.K. are holders of a Ph.D. Fellowship from the FWO. P.P. is grateful to Camilla degli Scrovegni for continuous support. P.P. is supported by the Italian Ministry of Education, University and Research, the Italian Ministry of Health, Telethon (GGP15219/B), the Italian Association for Cancer Research (IG-18624), and by local funds from the University of Ferrara. C.G. is supported by local funds from the University of Ferrara, the Italian Association for Cancer Research, the Italian Ministry of Health, and by Cariplo grant. G.B., J.B.P., and P.P. are part of the FWO—Scientific Research Community Casign (W0.019.17N).

Author details

¹Department of Cellular and Molecular Medicine and Leuven Kanker Instituut, KU Leuven, Laboratory of Molecular and Cellular Signaling, Leuven, Belgium. ²Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. ³Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Italy. ⁴CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 31 July 2017 Revised: 27 October 2017 Accepted: 3 November 2017

Published online: 28 February 2018

References

- Rizzuto, R., De Stefani, D., Raffaello, A. & Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. *Nat. Rev. Mol. Cell. Biol.* **13**, 566–578 (2012).
- Mesmin B. Mitochondrial lipid transport and biosynthesis: a complex balance. *J. Cell Biol.* **214**, 9–11 (2016).
- Wang, C. & Youle, R. J. The role of mitochondria in apoptosis. *Annu. Rev. Genet.* **43**, 95–118 (2009).
- Antico Arciuch, V. G., Elguero, M. E., Poderoso, J. J. & Carreras, M. C. Mitochondrial regulation of cell cycle and proliferation. *Antioxid. Redox Signal.* **16**, 1150–1180 (2012).
- Okamoto, K. & Kondo-Okamoto, N. Mitochondria and autophagy: critical interplay between the two homeostats. *Biochim. Biophys. Acta* **1820**, 595–600 (2012).
- Ivanova, H., Kerkhofs, M., La Rovere, R. M. & Bultynck, G. Endoplasmic reticulum-mitochondrial Ca²⁺ fluxes underlying cancer cell survival. *Front. Oncol.* **7**, 70 (2017).
- Schrepfer, E. & Scorrano, L. Mitofusins, from mitochondria to metabolism. *Mol. Cell* **61**, 683–694 (2016).
- Vance, J. E. MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. *Biochim. Biophys. Acta* **1841**, 595–609 (2014).
- Demarquoy, J. & Le Borgne, F. Crosstalk between mitochondria and peroxisomes. *World J. Biol. Chem.* **6**, 301–309 (2015).
- Stefan, C. J., Manford, A. G. & Emr, S. D. ER-PM connections: sites of information transfer and inter-organelle communication. *Curr. Opin. Cell Biol.* **25**, 434–442 (2013).

11. Giacomello, M. & Pellegrini, L. The coming of age of the mitochondria-ER contact: a matter of thickness. *Cell Death. Differ.* **23**, 1417–1427 (2016).
12. Vance, J. E. Phospholipid synthesis in a membrane fraction associated with mitochondria. *J. Biol. Chem.* **265**, 7248–7256 (1990).
13. van Vliet, A. R., Verfaillie, T. & Agostinis, P. New functions of mitochondria associated membranes in cellular signaling. *Biochim. Biophys. Acta* **1843**, 2253–2262 (2014).
14. Giorgi, C., Wieckowski, M. R., Pandolfi, P. P. & Pinton, P. Mitochondria associated membranes (MAMs) as critical hubs for apoptosis. *Commun. Integr. Biol.* **4**, 334–335 (2011).
15. Bononi, A. et al. Mitochondria-associated membranes (MAMs) as hotspot Ca²⁺ signaling units. *Adv. Exp. Med. Biol.* **740**, 411–437 (2012).
16. Hamasaki, M. et al. Autophagosomes form at ER-mitochondria contact sites. *Nature* **495**, 389–393 (2013).
17. Missiroli, S. et al. PML at mitochondria-associated membranes is critical for the repression of autophagy and cancer development. *Cell Rep.* **16**, 2415–2427 (2016).
18. Giorgi, C. et al. Mitochondria-associated membranes: composition, molecular mechanisms, and physiopathological implications. *Antioxid. Redox Signal.* **22**, 995–1019 (2015).
19. Wang, H. J., Guay, G., Pogan, L., Sauve, R. & Nabi, I. R. Calcium regulates the association between mitochondria and a smooth subdomain of the endoplasmic reticulum. *J. Cell. Biol.* **150**, 1489–1498 (2000).
20. Csordas, G. et al. Structural and functional features and significance of the physical linkage between ER and mitochondria. *J. Cell Biol.* **174**, 915–921 (2006).
21. Sood, A. et al. A Mitofusin-2-dependent inactivating cleavage of Opa1 links changes in mitochondria cristae and ER contacts in the postprandial liver. *Proc. Natl. Acad. Sci. USA* **111**, 16017–16022 (2014).
22. Clapham, D. E. Calcium signaling. *Cell* **131**, 1047–1058 (2007).
23. Bootman, M. D. Calcium signaling. *Cold Spring Harb. Perspect. Biol.* **4**, a011171 (2012).
24. Parys, J. B. & De Smedt, H. Inositol 1,4,5-trisphosphate and its receptors. *Adv. Exp. Med. Biol.* **740**, 255–279 (2012).
25. Lanner, J. T., Georgiou, D. K., Joshi, A. D., Hamilton, S. L. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. *Cold Spring Harb. Perspect. Biol.* **2**, a003996 (2010).
26. Gincel, D., Zaid, H. & Shoshan-Barmatz, V. Calcium binding and translocation by the voltage-dependent anion channel: a possible regulatory mechanism in mitochondrial function. *Biochem. J.* **358**(Pt. 1), 147–155 (2001).
27. Rapizzi, E. et al. Recombinant expression of the voltage-dependent anion channel enhances the transfer of Ca²⁺ microdomains to mitochondria. *J. Cell Biol.* **159**, 613–624 (2002).
28. Marchi, S. & Pinton, P. The mitochondrial calcium uniporter complex: molecular components, structure and physiopathological implications. *J. Physiol.* **592**, 829–839 (2014).
29. Foskett, J. K. & Philipson, B. The mitochondrial Ca²⁺ uniporter complex. *J. Mol. Cell Cardiol.* **78**, 3–8 (2015).
30. De Stefani, D., Rizzuto, R. & Pozzan, T. Enjoy the trip: calcium in mitochondria back and forth. *Annu. Rev. Biochem.* **85**, 161–192 (2016).
31. Csordas, G., Thomas, A. P. & Hajnoczky, G. Quasi-synaptic calcium signal transmission between endoplasmic reticulum and mitochondria. *EMBO J.* **18**, 96–108 (1999).
32. Denton, R. M. Regulation of mitochondrial dehydrogenases by calcium ions. *Biochim. Biophys. Acta* **1787**, 1309–1316 (2009).
33. Shanmughapriya, S. et al. Ca²⁺ signals regulate mitochondrial metabolism by stimulating CREB-mediated expression of the mitochondrial Ca²⁺ uniporter gene MCU. *Sci. Signal.* **8**, ra23 (2015).
34. Booth, D. M., Enyedi, B., Geiszt, M., Varnai, P. & Hajnoczky, G. Redox nanodomains are induced by and control calcium signaling at the ER-mitochondrial interface. *Mol. Cell* **63**, 240–248 (2016).
35. Glancy, B. & Balaban, R. S. Role of mitochondrial Ca²⁺ in the regulation of cellular energetics. *Biochemistry* **51**, 2959–2973 (2012).
36. Marmol, P. et al. Requirement for aralar and its Ca²⁺-binding sites in Ca²⁺ signal transduction in mitochondria from INS-1 clonal beta-cells. *J. Biol. Chem.* **284**, 515–524 (2009).
37. Gellerich, F. N. et al. Extramitochondrial Ca²⁺ in the nanomolar range regulates glutamate-dependent oxidative phosphorylation on demand. *PLoS ONE* **4**, e8181 (2009).
38. Gellerich, F. N. et al. The regulation of OXPHOS by extramitochondrial calcium. *Biochim. Biophys. Acta* **1797**, 1018–1027 (2010).
39. Gellerich, F. N. et al. Cytosolic Ca²⁺ regulates the energization of isolated brain mitochondria by formation of pyruvate through the malate-aspartate shuttle. *Biochem. J.* **443**, 747–755 (2012).
40. Lasorsa, F. M. et al. Recombinant expression of the Ca²⁺-sensitive aspartate/glutamate carrier increases mitochondrial ATP production in agonist-stimulated Chinese hamster ovary cells. *J. Biol. Chem.* **278**, 38686–38692 (2003).
41. Paillard, M. et al. Tissue-specific mitochondrial decoding of cytoplasmic Ca²⁺ signals is controlled by the stoichiometry of MICU1/2 and MCU. *Cell Rep.* **18**, 2291–2300 (2017).
42. Csordas, G. et al. MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca²⁺ uniporter. *Cell Metab.* **17**, 976–987 (2013).
43. Patron, M. et al. MICU1 and MICU2 finely tune the mitochondrial Ca²⁺ uniporter by exerting opposite effects on MCU activity. *Mol. Cell* **53**, 726–737 (2014).
44. Kamer, K. J., Grabarek, Z. & Mootha, V. K. High-affinity cooperative Ca²⁺ binding by MICU1-MICU2 serves as an on-off switch for the uniporter. *EMBO Rep.* **18**, 1397–1411 (2017).
45. Liu, J. C. et al. MICU1 serves as a molecular gatekeeper to prevent in vivo mitochondrial calcium overload. *Cell Rep.* **16**, 1561–1573 (2016).
46. Morciano, G. et al. Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury. *J. Mol. Cell. Cardiol.* **78**, 142–153 (2015).
47. Bonora, M. et al. Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation. *EMBO Rep.* **18**, 1077–1089 (2017).
48. Pinton, P., Giorgi, C., Siviero, R., Zecchini, E. & Rizzuto, R. Calcium and apoptosis: ER-mitochondria Ca²⁺ transfer in the control of apoptosis. *Oncogene* **27**, 6407–6418 (2008).
49. Decuypere, J. P. et al. The IP₃ receptor-mitochondria connection in apoptosis and autophagy. *Biochim. Biophys. Acta* **1813**, 1003–1013 (2011).
50. Halestrap, A. P. The C ring of the F1FO ATP synthase forms the mitochondrial permeability transition pore: a critical appraisal. *Front. Oncol.* **4**, 234 (2014).
51. Danese, A. et al. Calcium regulates cell death in cancer: roles of the mitochondria and mitochondria-associated membranes (MAMs). *Biochim. Biophys. Acta* **1858**, 615–627 (2017).
52. Hwang, M. S. et al. Mitochondrial Ca²⁺ influx targets cardiolipin to disintegrate respiratory chain complex II for cell death induction. *Cell Death. Differ.* **21**, 1733–1745 (2014).
53. Giorgio, V. et al. Ca²⁺ binding to F-ATP synthase beta subunit triggers the mitochondrial permeability transition. *EMBO Rep.* **18**, 1065–1076 (2017).
54. Rizzuto, R., Brini, M., Murgia, M. & Pozzan, T. Microdomains with high Ca²⁺ close to IP₃-sensitive channels that are sensed by neighboring mitochondria. *Science* **262**, 744–747 (1993).
55. Szabadkai, G. et al. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca²⁺ channels. *J. Cell Biol.* **175**, 901–911 (2006).
56. Giorgi, C. et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. *Science* **330**, 1247–1251 (2010).
57. Bononi, A. et al. Identification of PTEN at the ER and MAMs and its regulation of Ca²⁺ signaling and apoptosis in a protein phosphatase-dependent manner. *Cell Death. Differ.* **20**, 1631–1643 (2013).
58. Filadi, R. et al. Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling. *Proc. Natl. Acad. Sci. USA* **112**, E2174–E2181 (2015).
59. de Brito, O. M. & Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. *Nature* **456**, 605–610 (2008).
60. Verfaillie, T. et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. *Cell Death. Differ.* **19**, 1880–1891 (2012).
61. Doghman-Bouguerra, M. et al. FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria. *EMBO Rep.* **17**, 1264–1280 (2016).
62. Bultynck, G., Parys, J. B. Ca²⁺ signaling and cell death: focus on Ca²⁺-transport systems and their implication in cell death and survival. *Cell Calcium* **69**, 1–3 (2018).
63. De Stefani, D. et al. VDAC1 selectively transfers apoptotic Ca²⁺ signals to mitochondria. *Cell Death. Differ.* **19**, 267–273 (2012).
64. Mendes, C. C. et al. The type III inositol 1,4,5-trisphosphate receptor preferentially transmits apoptotic Ca²⁺ signals into mitochondria. *J. Biol. Chem.* **280**, 40892–40900 (2005).

65. Ivanova, H. et al. Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival. *Biochim. Biophys. Acta* **1843**, 2164–2183 (2014).
66. Giorgi, C. et al. p53 at the endoplasmic reticulum regulates apoptosis in a Ca²⁺-dependent manner. *Proc. Natl. Acad. Sci. USA* **112**, 1779–1784 (2015).
67. Lynes, E. M. et al. Palmitoylation is the switch that assigns calnexin to quality control or ER Ca²⁺ signaling. *J. Cell Sci.* **126**(Pt. 17), 3893–3903 (2013).
68. Simmen, T., Lynes, E. M., Gesson, K. & Thomas, G. Oxidative protein folding in the endoplasmic reticulum: tight links to the mitochondria-associated membrane (MAM). *Biochim. Biophys. Acta* **1798**, 1465–1473 (2010).
69. Brini, M. & Carafoli, E. Calcium pumps in health and disease. *Physiol. Rev.* **89**, 1341–1378 (2009).
70. Pinton, P. et al. Reduced loading of intracellular Ca²⁺ stores and down-regulation of capacitative Ca²⁺ influx in Bcl-2-overexpressing cells. *J. Cell Biol.* **148**, 857–862 (2000).
71. Foyouzi-Youssefi, R. et al. Bcl-2 decreases the free Ca²⁺ concentration within the endoplasmic reticulum. *Proc. Natl. Acad. Sci. USA* **97**, 5723–5728 (2000).
72. Pinton, P. et al. The Ca²⁺ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. *EMBO J.* **20**, 2690–2701 (2001).
73. Chami, M. et al. Role of SERCA1 truncated isoform in the proapoptotic calcium transfer from ER to mitochondria during ER stress. *Mol. Cell* **32**, 641–651 (2008).
74. Chami, M. et al. SERCA1 truncated proteins unable to pump calcium reduce the endoplasmic reticulum calcium concentration and induce apoptosis. *J. Cell Biol.* **153**, 1301–1314 (2001).
75. Herrera-Cruz, M. S. & Simmen, T. Cancer: untethering mitochondria from the endoplasmic reticulum? *Front. Oncol.* **7**, 105 (2017).
76. Bittremieux, M., Parys, J. B., Pinton, P. & Bultynck, G. ER functions of oncogenes and tumor suppressors: modulators of intracellular Ca²⁺ signaling. *Biochim. Biophys. Acta* **1863**, 1364–1378 (2016).
77. Akl, H. & Bultynck, G. Altered Ca²⁺ signaling in cancer cells: proto-oncogenes and tumor suppressors targeting IP₃ receptors. *Biochim. Biophys. Acta* **1835**, 180–193 (2013).
78. Szado, T. et al. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca²⁺ release and apoptosis. *Proc. Natl. Acad. Sci. USA* **105**, 2427–2432 (2008).
79. Bittremieux, M. & Bultynck, G. p53 and Ca²⁺ signaling from the endoplasmic reticulum: partners in anti-cancer therapies. *Oncoscience* **2**, 233–238 (2015).
80. Kroemer, G., Bravo-San Pedro, J. M. & Galluzzi, L. Novel function of cytoplasmic p53 at the interface between mitochondria and the endoplasmic reticulum. *Cell Death Dis.* **6**, e1698 (2015).
81. Monaco, G. et al. The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca²⁺ signals to mitochondria. *J. Biol. Chem.* **290**, 9150–9161 (2015).
82. Vervliet, T. et al. Modulation of Ca²⁺ signaling by anti-apoptotic B-cell lymphoma 2 proteins at the endoplasmic reticulum-mitochondrial interface. *Front. Oncol.* **7**, 75 (2017).
83. Rong, Y. & Distelhorst, C. W. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. *Annu. Rev. Physiol.* **70**, 73–91 (2008).
84. Vervliet, T., Parys, J. B. & Bultynck, G. Bcl-2 proteins and calcium signaling: complexity beneath the surface. *Oncogene* **35**, 5079–5092 (2016).
85. Rong, Y. P. et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP₃ receptor. *Proc. Natl. Acad. Sci. USA* **106**, 14397–14402 (2009).
86. Zhong, F. et al. Induction of Ca²⁺-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP₃ receptor interaction. *Blood* **117**, 2924–2934 (2011).
87. Monaco, G. et al. Selective regulation of IP₃-receptor-mediated Ca²⁺ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-XL. *Cell. Death Differ.* **19**, 295–309 (2012).
88. Monaco, G. et al. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for BH4 domain in both protein stability and function. *FEBS J* **285**, 127–145 (2018).
89. Ivanova, H. et al. The trans-membrane domain of Bcl-2alpha, but not its hydrophobic cleft, is a critical determinant for efficient IP₃ receptor inhibition. *Oncotarget* **7**, 55704–55720 (2016).
90. Xu, L. et al. Suppression of IP₃-mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase 1. *Mol. Cell. Biochem.* **295**, 153–165 (2007).
91. Chang, M. J. et al. Feedback regulation mediated by Bcl-2 and DARPP-32 regulates inositol 1,4,5-trisphosphate receptor phosphorylation and promotes cell survival. *Proc. Natl. Acad. Sci. USA* **111**, 1186–1191 (2014).
92. Eckenrode, E. F., Yang, J., Velmurugan, G. V., Foskett, J. K. & White, C. Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca²⁺ signaling. *J. Biol. Chem.* **285**, 13678–13684 (2010).
93. Monaco, G. et al. Profiling of the Bcl-2/Bcl-X_L-binding sites on type 1 IP₃ receptor. *Biochem. Biophys. Res. Commun.* **428**, 31–35 (2012).
94. White, C. et al. The endoplasmic reticulum gateway to apoptosis by Bcl-X_L modulation of the InsP₃R. *Nat. Cell Biol.* **7**, 1021–1028 (2005).
95. Akl, H. et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. *Biochim. Biophys. Acta* **1843**, 2240–2252 (2014).
96. Abu-Hamad, S. et al. The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. *J. Cell Sci.* **122**, 1906–1916 (2009).
97. Arbel, N. & Shoshan-Barmatz, V. Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity. *J. Biol. Chem.* **285**, 6053–6062 (2010).
98. Shimizu, S., Konishi, A., Kodama, T. & Tsujimoto, Y. BH4 domain of anti-apoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. *Proc. Natl. Acad. Sci. USA* **97**, 3100–3105 (2000).
99. Naon, D. & Scorrano, L. At the right distance: ER-mitochondria juxtaposition in cell life and death. *Biochim. Biophys. Acta* **1843**, 2184–2194 (2014).
100. Marchi, S. et al. Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death. *Cell Calcium* **69**, 62–72 (2018).
101. Naon, D. et al. Critical reappraisal confirms that Mitofusin 2 is an endoplasmic reticulum-mitochondria tether. *Proc. Natl. Acad. Sci. USA* **113**, 11249–11254 (2016).
102. Monteith, G. R., Davis, F. M. & Roberts-Thomson, S. J. Calcium channels and pumps in cancer: changes and consequences. *J. Biol. Chem.* **287**, 31666–31673 (2012).
103. Monteith, G. R., Prevarskaya, N. & Roberts-Thomson, S. J. The calcium-cancer signalling nexus. *Nat. Rev. Cancer* **17**, 367–380 (2017).
104. Zhang, G. et al. Decreased expression of microRNA-320a promotes proliferation and invasion of non-small cell lung cancer cells by increasing VDAC1 expression. *Oncotarget* **7**, 49470–49480 (2016).
105. Wu, C. H., Lin, Y. W., Wu, T. F., Ko, J. L. & Wang, P. H. Clinical implication of voltage-dependent anion channel 1 in uterine cervical cancer and its action on cervical cancer cells. *Oncotarget* **7**, 4210–4225 (2016).
106. Arif, T., Vasilkovsky, L., Refaely, Y., Konson, A. & Shoshan-Barmatz, V. Silencing VDAC1 expression by siRNA inhibits cancer cell proliferation and tumor growth in vivo. *Mol. Ther. Nucleic Acids* **8**, 493 (2017).
107. Shoshan-Barmatz, V., Krelin, Y., Shteinfein-Kuzmine, A. & Arif, T. Voltage-dependent anion channel 1 as an emerging drug target for novel anti-cancer therapeutics. *Front. Oncol.* **7**, 154 (2017).
108. Prevarskaya, N., Ouadid-Ahidouch, H., Skryma, R. & Shuba, Y. Remodelling of Ca²⁺ transport in cancer: how it contributes to cancer hallmarks? *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **369**, 20130097 (2014).
109. Tsunoda, T. et al. Inositol 1,4,5-trisphosphate IP₃ receptor type 1 (IP₃R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. *Oncogene* **24**, 1396–1402 (2005).
110. Gelebart, P. et al. Expression of endomembrane calcium pumps in colon and gastric cancer cells. Induction of SERCA3 expression during differentiation. *J. Biol. Chem.* **277**, 26310–26320 (2002).
111. Bultynck, G. & Campanella, M. Tumor suppressive Ca²⁺ signaling is driven by IP₃ receptors' fitness. *Cell Stress* **1**, 73–78 (2017).
112. Chen, B. B., Glasser, J. R., Coon, T. A. & Mallampalli, R. K. FBXL2 is a ubiquitin E3 ligase subunit that triggers mitotic arrest. *Cell Cycle* **10**, 3487–3494 (2011).
113. Kuchay, S. et al. PTEN counteracts FBXL2 to promote IP₃R3- and Ca²⁺-mediated apoptosis limiting tumour growth. *Nature* **546**, 554–558 (2017).
114. Bononi, A. et al. BAP1 regulates IP₃R3-mediated Ca²⁺ flux to mitochondria suppressing cell transformation. *Nature* **546**, 549–553 (2017).
115. Marchi, S. et al. Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25. *Curr. Biol.* **23**, 58–63 (2013).
116. Tosatto, A. et al. The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1alpha. *EMBO Mol. Med.* **8**, 569–585 (2016).
117. Kania, E., Roest, G., Vervliet, T., Parys, J. B. & Bultynck, G. IP₃ receptor-mediated calcium signaling and its role in autophagy in cancer. *Front. Oncol.* **7**, 140 (2017).

118. Green, D. R. A BH3 mimetic for killing cancer cells. *Cell* **165**, 1560 (2016).
119. Anderson, M. A. et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. *Blood* **127**, 3215–3224 (2016).
120. Mignen, O. et al. Constitutive calcium entry and cancer: updated views and insights. *Eur. Biophys. J.* **46**, 395–413 (2017).
121. Chen, Y. F., Hsu, K. F. & Shen, M. R. The store-operated Ca^{2+} entry-mediated signaling is important for cancer spread. *Biochim. Biophys. Acta* **1863**, 1427–1435 (2016).
122. Deliot, N. & Constantin, B. Plasma membrane calcium channels in cancer: alterations and consequences for cell proliferation and migration. *Biochim. Biophys. Acta* **1848**(10 Pt. B), 2512–2522 (2015).
123. Wyrsch, P., Blenn, C., Pesch, T., Beneke, S. & Althaus, F. R. Cytosolic Ca^{2+} shifts as early markers of cytotoxicity. *Cell Commun. Signal.* **11**, 11 (2013).
124. Giorgi, C. et al. Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling. *Oncotarget* **6**, 1435–1445 (2015).
125. Bonora, M., Giorgi, C. & Pinton, P. Novel frontiers in calcium signaling: a possible target for chemotherapy. *Pharmacol. Res.* **99**, 82–85 (2015).
126. Wang, T. F., Zhou, C., Tang, A. H., Wang, S. Q. & Chai, Z. Cellular mechanism for spontaneous calcium oscillations in astrocytes. *Acta Pharmacol. Sin.* **27**, 861–868 (2006).
127. Akl, H. et al. HA14-1, but not the BH3 mimetic ABT-737, causes Ca^{2+} dysregulation in platelets and human cell lines. *Haematologica* **98**, e49–e51 (2013).
128. Vervoessem, T., Ivanova, H., Luyten, T., Parys, J. B. & Bultynck, G. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca^{2+} signaling. *Biochim. Biophys. Acta* **1864**, 968–976 (2017).
129. Cull, E. H. & Altman, J. K. Contemporary treatment of APL. *Curr. Hematol. Malig. Rep.* **9**, 193–201 (2014).
130. Salomoni, P., Ferguson, B. J., Wyllie, A. H. & Rich, T. New insights into the role of PML in tumour suppression. *Cell. Res.* **18**, 622–640 (2008).
131. Alimoghaddam, K. A review of arsenic trioxide and acute promyelocytic leukemia. *Int. J. Hematol. Oncol. Stem Cell Res.* **8**, 44–54 (2014).
132. McCulloch, D., Brown, C. & Iland, H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. *Oncotargets Ther.* **10**, 1585–1601 (2017).
133. Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. *J. Exp. Med.* **193**, 1361–1371 (2001).
134. Maes, H., Rubio, N., Garg, A. D. & Agostinis, P. Autophagy: shaping the tumor microenvironment and therapeutic response. *Trends Mol. Med.* **19**, 428–446 (2013).
135. Gurrieri, C. et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. *J. Natl. Cancer Inst.* **96**, 269–279 (2004).
136. Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* **13**, 132–141 (2011).
137. Nazio, F. et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. *Nat. Cell Biol.* **15**, 406–416 (2013).
138. Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms of action. *Eur. J. Pharmacol.* **740**, 364–378 (2014).
139. Wozniak, K. & Blasiak, J. Recognition and repair of DNA-cisplatin adducts. *Acta Biochim. Pol.* **49**, 583–596 (2002).
140. Xu, Y. et al. Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis. *Oncol. Rep.* **34**, 3051–3060 (2015).
141. Huang, Z. et al. Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. *Acta Biochim. Biophys. Sin. (Shanghai)*. **39**, 835–843 (2007).
142. Schaaf, A. et al. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. *Urol. Oncol.* **22**, 188–192 (2004).
143. Xie, Q. et al. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca^{2+} signal transduction in human ovarian cancer cells. *Int. J. Oncol.* **49**, 2507–2519 (2016).
144. Florea, A. M. et al. Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma. *Oncotarget* **8**, 22876–22893 (2017).
145. Delbridge, A. R. & Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. *Cell. Death Differ.* **22**, 1071–1080 (2015).
146. Billard, C. BH3 mimetics: status of the field and new developments. *Mol. Cancer Ther.* **12**, 1691–1700 (2013).
147. Lee, E. F. et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. *J. Cell. Biol.* **180**, 341–355 (2008).
148. Vervoessem, T. et al. Bcl-2 inhibitors as anti-cancer therapeutics: the impact of and on calcium signaling. *Cell Calcium* (2017). pii: S0143-4160(17)30103-3. <https://doi.org/10.1016/j.ceca.2017.05.014> (in press).
149. Vogler, M. et al. BCL2/BCL-X_L inhibition induces apoptotic, disrupts cellular calcium homeostasis, and prevents platelet activation. *Blood* **117**, 7145–7154 (2011).
150. Mason, K. D. et al. Programmed anuclear cell death delimits platelet life span. *Cell* **128**, 1173–1186 (2007).
151. Schoenwaelder, S. M. & Jackson, S. P. Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function. *Blood* **119**, 1320–1321 (2012). author reply 1321–1322.
152. Harper, M. T. & Poole, A. W. Bcl-xL-inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores. *Blood* **119**, 4337–4338 (2012).
153. Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat. Med.* **19**, 202–208 (2013).
154. Lavi, A. R. et al. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. *Oncotarget* **6**, 27388–27402 (2015).
155. Akl, H. et al. IP₃R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP₃R-derived peptide targeting the BH4 domain of Bcl-2. *Cell Death Dis.* **4**, e632 (2013).
156. Greenberg, E. F. et al. Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263. *Cell Death Dis.* **6**, e2034 (2015).
157. Vervoessem, T. et al. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax. *Oncotarget* **8**, 111656–111671 (2017).
158. Fan, Z. et al. ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics. *Exp. Cell. Res.* **335**, 68–81 (2015).
159. Hermanson, D. et al. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. *Mol. Pharmacol.* **76**, 667–678 (2009).
160. Gerasimenko, J., Ferdek, P., Fischer, L., Gukovskaya, A. S. & Pandol, S. J. Inhibitors of Bcl-2 protein family deplete ER Ca^{2+} stores in pancreatic acinar cells. *Pflug. Arch.* **460**, 891–900 (2010).
161. Ferdek, P. E. et al. BH3 mimetic-elicited Ca^{2+} signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca^{2+} -like peptides. *Cell Death Dis.* **8**, e2640 (2017).
162. Ferdek, P. E. & Jakubowska, M. A. On BH3 mimetics and Ca^{2+} signaling. *Drug Dev. Res.* **78**, 313–318 (2017).
163. Varoni, E. M., Lo Faro, A. F., Sharifi-Rad, J. & Iriti, M. Anticancer molecular mechanisms of Resveratrol. *Front. Nutr.* **3**, 8 (2016).
164. Aluyen, J. K. et al. Resveratrol: potential as anticancer agent. *J. Diet. Suppl.* **9**, 45–56 (2012).
165. Kulkarni, S. S. & Canto, C. The molecular targets of resveratrol. *Biochim. Biophys. Acta* **1852**, 1114–1123 (2015).
166. Madreiter-Sokolowski, C. T. et al. Resveratrol specifically kills cancer cells by a devastating increase in the Ca^{2+} coupling between the greatly tethered endoplasmic reticulum and mitochondria. *Cell. Physiol. Biochem.* **39**, 1404–1420 (2016).
167. Wang, W. A., Groenendyk, J. & Michalak, M. Endoplasmic reticulum stress associated responses in cancer. *Biochim. Biophys. Acta* **1843**, 2143–2149 (2014).
168. Dolfi, S. C. et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. *Cancer Metab.* **1**, 20 (2013).
169. Cardenas, C. et al. Selective vulnerability of cancer cells by inhibition of Ca^{2+} transfer from endoplasmic reticulum to mitochondria. *Cell Rep.* **14**, 2313–2324 (2016).
170. Bultynck, G. Onco-IP₃Rs feed cancerous cravings for mitochondrial Ca^{2+} . *Trends Biochem. Sci.* **41**, 390–393 (2016).
171. Dadi, P. K., Ahmad, M. & Ahmad, Z. Inhibition of ATPase activity of Escherichia coli ATP synthase by polyphenols. *Int. J. Biol. Macromol.* **45**, 72–79 (2009).

172. Gledhill, J. R. & Walker, J. E. Inhibition sites in F1-ATPase from bovine heart mitochondria. *Biochem. J.* **386**, 591–598 (2005).
173. Zheng, J. & Ramirez, V. D. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. *Biochem. Biophys. Res. Commun.* **261**, 499–503 (1999).
174. Zheng, J. & Ramirez, V. D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. *Br. J. Pharmacol.* **130**, 1115–1123 (2000).
175. Luyten, T. et al. Resveratrol-induced autophagy is dependent on IP₃Rs and on cytosolic Ca²⁺. *Biochim. Biophys. Acta* **1864**, 947–956 (2017).
176. Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. *J. Pharm. Pharmacol.* **65**, 157–170 (2013).
177. Rivankar, S. An overview of doxorubicin formulations in cancer therapy. *J. Cancer Res. Ther.* **10**, 853–858 (2014).
178. Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochem. Pharmacol.* **57**, 727–741 (1999).
179. Hanusova, V., Bousova, I. & Skalova, L. Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. *Drug. Metab. Rev.* **43**, 540–557 (2011).
180. Volkova, M. & Russell, R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. *Curr. Cardiol. Rev.* **7**, 214–220 (2011).
181. Giorgi, C. et al. Alterations in mitochondrial and endoplasmic reticulum signaling by p53 mutants. *Front. Oncol.* **6**, 42 (2016).
182. Ji, M. M. et al. Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP₃-mediated PRKAA activation. *Autophagy* **11**, 2160–2171 (2015).
183. Beloribi-Djefafia, S., Vasseur, S. & Guillaumond, F. Lipid metabolic reprogramming in cancer cells. *Oncogenesis* **5**, e189 (2016).
184. Rios-Marco, P. et al. Alkylphospholipids deregulate cholesterol metabolism and induce cell-cycle arrest and autophagy in U-87 MG glioblastoma cells. *Biochim. Biophys. Acta* **1831**, 1322–1334 (2013).
185. Li, Y. et al. Enrichment of endoplasmic reticulum with cholesterol inhibits sarcoplasmic-endoplasmic reticulum calcium ATPase-2b activity in parallel with increased order of membrane lipids: implications for depletion of endoplasmic reticulum calcium stores and apoptosis in cholesterol-loaded macrophages. *J. Biol. Chem.* **279**, 37030–37039 (2004).
186. Lalli, E. Mitotane revisited: a new target for an old drug. *Endocrinology* **156**, 3873–3875 (2015).
187. Berruti, A. et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **23**(Suppl 7), vii131–vii138 (2012).
188. Berruti, A. et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. *J. Clin. Endocrinol. Metab.* **102**, 1358–1365 (2017).
189. Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. *N. Engl. J. Med.* **366**, 2189–2197 (2012).
190. Sbiera, S. et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. *Endocrinology* **156**, 3895–3908 (2015).
191. Doghman, M. et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. *Mol. Endocrinol.* **21**, 2968–2987 (2007).
192. Yang, X. A. et al. Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues. *Lab. Invest.* **85**, 205–213 (2005).